Clinical Trial

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-08-05; most recent amendment 2026-07-02.
Trial Details
NCT Number NCT07107230
Lead Sponsor Janssen Research & Development, LLC
Conditions Colorectal Neoplasms
Enrollment 380 participants
Start Date 2025-07-15
Primary Completion 2027-11-18 (estimated)
Study Completion 2028-04-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-06